I-Mab to Participate in Leerink Partners Global Healthcare Conference
I-Mab (NASDAQ: IMAB), a US-based global biotech company focused on precision immune-oncology agents for cancer treatment, has announced its participation in the Leerink Partners Global Healthcare Conference. The conference will take place in Miami, Florida on March 11-12, 2025, where I-Mab's management team will engage in one-on-one meetings with conference attendees.
I-Mab (NASDAQ: IMAB), un'azienda biotecnologica globale con sede negli Stati Uniti, specializzata in agenti immuno-oncologici di precisione per il trattamento del cancro, ha annunciato la sua partecipazione alla Conferenza Globale sulla Salute di Leerink Partners. La conferenza si terrà a Miami, Florida il 11-12 marzo 2025, dove il team di gestione di I-Mab parteciperà a incontri individuali con i partecipanti alla conferenza.
I-Mab (NASDAQ: IMAB), una empresa biotecnológica global con sede en Estados Unidos, centrada en agentes de inmuno-oncología de precisión para el tratamiento del cáncer, ha anunciado su participación en la Conferencia Global de Salud de Leerink Partners. La conferencia se llevará a cabo en Miami, Florida el 11-12 de marzo de 2025, donde el equipo de gestión de I-Mab se reunirá en encuentros individuales con los asistentes a la conferencia.
I-Mab (NASDAQ: IMAB), 미국에 본사를 둔 글로벌 생명공학 회사로, 암 치료를 위한 정밀 면역종양학 제제에 집중하고 있으며, 리어링크 파트너스 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 컨퍼런스는 2025년 3월 11-12일 플로리다주 마이애미에서 열리며, I-Mab의 경영진 팀이 컨퍼런스 참석자들과 일대일 회의를 진행할 예정입니다.
I-Mab (NASDAQ: IMAB), une entreprise biopharmaceutique mondiale basée aux États-Unis, spécialisée dans les agents d'immuno-oncologie de précision pour le traitement du cancer, a annoncé sa participation à la Conférence Mondiale sur la Santé de Leerink Partners. La conférence se tiendra à Miami, Floride, les 11 et 12 mars 2025, où l'équipe de direction d'I-Mab participera à des réunions individuelles avec les participants de la conférence.
I-Mab (NASDAQ: IMAB), ein in den USA ansässiges globales Biotechnologieunternehmen, das sich auf präzise immunonkologische Wirkstoffe zur Krebsbehandlung spezialisiert hat, hat seine Teilnahme an der Leerink Partners Global Healthcare Conference bekannt gegeben. Die Konferenz findet am 11. und 12. März 2025 in Miami, Florida statt, wo das Management-Team von I-Mab Einzelgespräche mit den Teilnehmern der Konferenz führen wird.
- None.
- None.
ROCKVILLE, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a US-based, global biotech company, exclusively focused on the development of precision immune-oncology agents for the treatment of cancer, today announced that members of I-Mab’s management will participate in one-on-one meetings at the Leerink Partners Global Healthcare Conference in Miami, Florida on Tuesday and Wednesday, March 11-12, 2025.
About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based, global biotech company, exclusively focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.
I-Mab Investor & Media Contacts
PJ Kelleher
LifeSci Advisors
+1-617-430-7579
pkelleher@lifesciadvisors.com
IR@imabbio.com
FAQ
When is I-Mab (IMAB) participating in the Leerink Partners Global Healthcare Conference 2025?
What type of meetings will IMAB management conduct at the Leerink Partners Conference 2025?
Where is the 2025 Leerink Partners Global Healthcare Conference being held for IMAB?
What is I-Mab's (IMAB) current business focus according to their latest conference participation?
